siRNAsense

siRNAsense is a Portuguese biotechnology company specializing in the development of advanced RNA interference (RNAi) therapies for respiratory diseases. Spun off from the i3S - Institute for Research and Innovation in Health at the University of Porto, the company utilizes a proprietary nanoparticle-based delivery platform to overcome the stability and delivery challenges associated with small interfering RNA (siRNA). Their lead programs focus on silencing specific genes involved in chronic lung inflammation, aiming to provide more effective and less invasive treatment options for conditions like asthma and COPD. By targeting the underlying genetic drivers of disease directly in the respiratory tract, siRNAsense seeks to minimize systemic side effects. The company is currently advancing its pipeline through pre-clinical validation and seeking strategic partnerships for clinical development.